4&#39;-substituted nucleoside derivatives as inhibitors of hcv rna replication

ABSTRACT

The present invention relates to the use of nucleoside derivatives of formula I 
     
       
         
         
             
             
         
       
         
         
           
             wherein B signifies a 9-purinyl residue B1 of formula 
           
         
       
    
     
       
         
         
             
             
         
       
         
         
           
             or a 1-pyrimidyl residue B2 of formula 
           
         
       
    
     
       
         
         
             
             
         
       
         
         
           
             wherein the symbols are as defined in the specification, 
             and of pharmaceutically acceptable salts thereof;
 
for the treatment of diseases mediated by the Hepatitis C Virus (HCV), for the preparation of a medicament for such treatment and to pharmaceutical compositions containing such compounds.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is divisional of U.S. Ser. No. 12/561,097 filed on Sep.16, 2009, which is a divisional of U.S. Ser. No. 10/891,967 filed Jul.15, 2004 which is a divisional of Ser. No. 10/167,106, filed Jun. 11,2002, now issued as U.S. Pat. No. 6,784,166 granted Aug. 31, 2004, whichclaims benefit under Title 35, United States Code, §119 of Great BritainPatent Application No. 00114286.8, filed on Jun. 12, 2001.

BACKGROUND OF THE INVENTION

The invention relates to nucleoside derivatives as inhibitors of HCVreplicon RNA replication. In particular, the invention is concerned withthe use of purine and pyrimidine nucleoside derivatives as inhibitors ofsubgenomic Hepatitis C Virus (HCV) RNA replication and pharmaceuticalcompositions containing such compounds.

Hepatitis C virus is the leading cause of chronic liver diseasethroughout the world. Patients infected with HCV are at risk ofdeveloping cirrhosis of the liver and subsequent hepatocellularcarcinoma and hence HCV is the major indication for livertransplantation. Only two approved therapies are currently available forthe treatment of HCV infection (R. G. Gish, Sem. Liver. Dis., 1999, 19,35). These are interferon-α monotherapy and, more recently, combinationtherapy of the nucleoside analogue, ribavirin (Virazole), withinterferon-α.

Many of the drugs approved for the treatment of viral infections arenucleosides or nucleoside analogues and most of these nucleosideanalogue drugs inhibit viral replication, following conversion to thecorresponding triphosphates, through inhibition of the viral polymeraseenzymes. This conversion to the triphosphate is commonly mediated bycellular kinases and therefore the direct evaluation of nucleosides asinhibitors of HCV replication is only conveniently carried out using acell-based assay. For HCV the availability of a true cell-based viralreplication assay or animal model of infection is lacking.

Hepatitis C virus belongs to the family of Flaviridae. It is an RNAvirus, the RNA genome encoding a large polyprotein which afterprocessing produces the necessary replication machinery to ensuresynthesis of progeny RNA. It is believed that most of the non-structuralproteins encoded by the HCV RNA genome are involved in RNA replication.Lohmann et al. [V. Lohmann et al., Science, 1999, 285, 110-113] havedescribed the construction of a Human Hepatoma (Huh7) cell line in whichsubgenomic HCV RNA molecules have been introduced and shown to replicatewith high efficiency. It is believed that the mechanism of RNAreplication in these cell lines is identical to the replication of thefull length HCV RNA genome in infected hepatocytes. The subgenomic HCVcDNA clones used for the isolation of these cell lines have formed thebasis for the development of a cell-based assay for identifyingnucleoside analogue inhibitors of HCV replication.

SUMMARY OF THE INVENTION

The invention is concerned with the use of compounds of the formula Iawherein

the compound is in the D configuration;

R is hydrogen or —[P(O)(OH)]—O]_(n)H and n is 1, 2 or 3

R¹ is —N₃, C₃₋₆ alkenyl, C₃₋₆ alkynyl, C₂₋₆ alkoxy;

R² and R³ are independently hydrogen, —OH or —NR⁴ ₂;

R⁴ is hydrogen or C₁₋₃ alkyl;

or a pharmaceutically acceptable salt thereof.

for the treatment of diseases mediated by the Hepatitis C Virus (HCV)and for pharmaceutical compositions comprising such compounds.

DETAILED DESCRIPTION OF THE INVENTION

The compounds of formula I have been shown to be inhibitors ofsubgenomic Hepatitis C Virus replication in a hepatoma cell line. Thesecompounds have the potential to be efficacious as antiviral drugs forthe treatment of HCV infections in human.

In compounds, wherein R is a phosphate group —[P(O)(OH)—O]_(n)H, n ispreferably 1. The phosphate group may be in the form of a stabilizedmonophosphate prodrug or other pharmaceutically acceptable leaving groupwhich when administered in vivo, is capable of providing a compoundwherein R is monophosphate. These “pronucleotides” can improve theproperties such as activity, bioavailability or stability of the parentnucleotide.

Examples of substituent groups which can replace one or more of thehydrogens in the phosphate moiety are described in C. R. Wagner et al.,Medicinal Research Reviews, 2000, 20(6), 417 or in R. Jones and N.Bischofberger, Antiviral Research 1995, 27, 1. Such pronucleotidesinclude alkyl and aryl phosphodiesters, steroid phosphodiesters, alkyland aryl phosphotriesters, cyclic alkyl phosphotriesters, cyclosaligenyl(CycloSal) phosphotriesters, S-acyl-2-thioethyl (SATE) derivatives,dithioethyl (DTE) derivatives, pivaloyloxymethyl phosphoesters,para-acyloxybenzyl (PAOB) phosphoesters, glycerolipid phosphodiesters,glycosyl lipid phosphotriesters, dinucleosidyl phosphodiesters,dinucleoside phosphotriesters, phosphorodiamidates, cyclicphosphoramidates, phosphoramidate monoesters and phosphoramidatediesters.

The invention also includes pro-drugs or bioprecursors of the parentnucleoside which are converted in vivo to the compound of formula Iwherein R is hydrogen, or at least one of R², R³ and R⁴ is hydroxy.Preferred pro-drug derivatives include carboxylic esters in which thenon-carbonyl moiety of the ester group is selected from straight orbranched alkyl (e.g. methyl, n-propyl, n-butyl or tert.-butyl),alkoxyalkyl (e.g. methoxymethyl), aralkyl (e.g. benzyl), aryloxyalkyl(e.g. phenoxymethyl), aryl (e.g. phenyl optionally substituted byhalogen, C₁₋₄ alkyl or C₁₋₄ alkoxy or amino); sulphonate esters such asalkylsulphonyl or arylsulphonyl (e.g. methanesulphonyl); amino acidesters (e.g. L-valyl or L-isoleucyl) or pharmaceutically acceptablesalts thereof. The preparation is carried out according to known methodsin the art, for example methods known from textbooks on organicchemistry (e.g. from J. March (1992), “Advanced Organic Chemistry:Reactions, Mechanisms, and Structure”, 4^(th) ed. John Wiley & Sons).

The term “alkyl” as used herein denotes a straight or branched chainhydrocarbon residue containing 1 to 12 carbon atoms. Preferably, theterm “alkyl” denotes a straight or branched chain hydrocarbon residuecontaining 1 to 7 carbon atoms. Most preferred are methyl, ethyl,propyl, isopropyl, n-butyl, isobutyl, tert.-butyl or pentyl. The alkylmay be unsubstituted or substituted. The substituents are selected fromone or more of cycloalkyl, nitro, amino, alkyl amino, dialkyl amino,alkyl carbonyl and cycloalkyl carbonyl.

The term “cycloalkyl” as used herein denotes an optionally substitutedcycloalkyl group containing 3 to 7 carbon atoms, e. g. cyclopropyl,cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.

The term “alkoxy” as used herein denotes an optionally substitutedstraight or branched chain alkyl-oxy group wherein the “alkyl” portionis as defined above such as methoxy, ethoxy, n-propyloxy, i-propyloxy,n-butyloxy, i-butyloxy, tert.-butyloxy, pentyloxy, hexyloxy, heptyloxyincluding their isomers.

The term “alkoxyalkyl” as used herein denotes an alkoxy group as definedabove which is bonded to an alkyl group as defined above. Examples aremethoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl, ethoxyethyl,ethoxypropyl, propyloxypropyl, methoxybutyl, ethoxybutyl,propyloxybutyl, butyloxybutyl, tert.-butyloxybutyl, methoxypentyl,ethoxypentyl, propyloxypentyl including their isomers.

The term “alkenyl” as used herein denotes an unsubstituted orsubstituted hydrocarbon chain radical having from 2 to 7 carbon atoms,preferably from 2 to 4 carbon atoms, and having one or two olefinicdouble bonds, preferably one olefinic double bond. Examples are vinyl,1-propenyl, 2-propenyl (allyl) or 2-butenyl (crotyl).

The term “alkynyl” as used herein denotes to unsubstituted orsubstituted hydrocarbon chain radical having from 2 to 7 carbon atoms,preferably 2 to 4 carbon atoms, and having one or where possible twotriple bonds, preferably one triple bond. Examples are ethynyl,1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl or 3-butynyl.

The term “hydroxyalkyl” as used herein denotes a straight or branchedchain alkyl group as defined above wherein 1, 2, 3 or more hydrogenatoms are substituted by a hydroxy group. Examples are hydroxymethyl,1-hydroxyethyl, 2-hydroxyethyl, 1-hydroxypropyl, 2-hydroxypropyl,3-hydroxypropyl, hydroxyisopropyl, hydroxybutyl and the like.

The term “haloalkyl” as used herein denotes a straight or branched chainalkyl group as defined above wherein 1, 2, 3 or more hydrogen atoms aresubstituted by a halogen. Examples are 1-fluoromethyl, 1-chloromethyl,1-bromomethyl, 1-iodomethyl, trifluoromethyl, trichloromethyl,tribromomethyl, triiodomethyl, 1-fluoroethyl, 1-chloroethyl,1-bromoethyl, 1-iodoethyl, 2-fluoroethyl, 2-chloroethyl, 2-bromoethyl,2-iodoethyl, 2,2-dichloroethyl, 3-bromopropyl or 2,2,2-trifluoroethyland the like.

The term “alkylthio” as used herein denotes a straight or branched chain(alkyl)S— group wherein the “alkyl” portion is as defined above.Examples are methylthio, ethylthio, n-propylthio, i-propylthio,n-butylthio, i-butylthio or tert.-butylthio.

The term “aryl” as used herein denotes an optionally substituted phenyland naphthyl (e. g. 1-naphthyl, 2-naphthyl or 3-naphthyl). Suitablesubstituents for aryl can be selected from those named for alkyl, inaddition however, halogen, hydroxy and optionally substituted alkyl,haloalkyl, alkenyl, alkynyl and aryloxy are substituents which can beadded to the selection.

The term “heterocyclyl” as used herein denotes an optionally substitutedsaturated, partially unsaturated or aromatic monocyclic, bicyclic ortricyclic heterocyclic systems which contain one or more hetero atomsselected from nitrogen, oxygen and sulfur which can also be fused to anoptionally substituted saturated, partially unsaturated or aromaticmonocyclic carbocycle or heterocycle.

Examples of suitable heterocycles are oxazolyl, isoxazolyl, furyl,tetrahydrofuryl, 1,3-dioxolanyl, dihydropyranyl, 2-thienyl, 3-thienyl,pyrazinyl, isothiazolyl, dihydrooxazolyl, pyrimidinyl, tetrazolyl,1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, pyrrolidinonyl,(N-oxide)-pyridinyl, 1-pyrrolyl, 2-pyrrolyl, triazolyl e. g.1,2,3-triazolyl or 1,2,4-triazolyl, 1-pyrazolyl, 2-pyrazolyl,4-pyrazolyl, piperidinyl, morpholinyl (e. g. 4-morpholinyl),thiomorpholinyl (e. g. 4-thiomorpholinyl), thiazolyl, pyridinyl,dihydrothiazolyl, imidazolidinyl, pyrazolinyl, piperazinyl,1-imidazolyl, 2-imidazolyl, 4-imidazolyl, thiadiazolyl e. g.1,2,3-thiadiazolyl, 4-methylpiperazinyl, 4-hydroxypiperidin-1-yl.

Suitable substituents for heterocyclyl can be selected from those namedfor alkyl, in addition however, optionally substituted alkyl, alkenyl,alkynyl, an oxo group (═O) or aminosulphonyl are substituents which canbe added to the selection.

The term “acyl” (“alkylcarbonyl”)as used herein denotes a group offormula C(═O)R wherein R is hydrogen, an unsubstituted or substitutedstraight or branched chain hydrocarbon residue containing 1 to 7 carbonatoms or a phenyl group. Most preferred acyl groups are those wherein Ris hydrogen, an unsubstituted straight chain or branched hydrocarbonresidue containing 1 to 4 carbon atoms or a phenyl group.

The term halogen stands for fluorine, chlorine, bromine or iodine,preferable fluorine, chlorine, bromine.

Within the invention the term “X” represents O, S or CH₂, preferably Oor CH₂. Most preferred “X” represents O.

Within the invention the term “Z” represents O or S, preferably O.

In the pictorial representation of the compounds given throughout thisapplication, a thickened tapered line (

) indicates a substituent which is above the plane of the ring to whichthe asymmetric carbon belongs and a dotted line (

) indicates a substituent which is below the plane of the ring to whichthe asymmetric carbon belongs.

Compounds of formula I exhibit stereoisomerism. These compounds can beany isomer of the compound of formula I or mixtures of these isomers.The compounds and intermediates of the present invention having one ormore asymmetric carbon atoms may be obtained as racemic mixtures ofstereoisomers which can be resolved.

Compounds of formula I exhibit tautomerism that means that the compoundsof this invention can exist as two or more chemical compounds that arecapable of facile interconversion. In many cases it merely means theexchange of a hydrogen atom between two other atoms, to either of whichit forms a covalent bond. Tautomeric compounds exist in a mobileequilibrium with each other, so that attempts to prepare the separatesubstances usually result in the formation of a mixture that shows allthe chemical and physical properties to be expected on the basis of thestructures of the components.

The most common type of tautomerism is that involving carbonyl, or keto,compounds and unsaturated hydroxyl compounds, or enols. The structuralchange is the shift of a hydrogen atom between atoms of carbon andoxygen, with the rearrangement of bonds. For example, in many aliphaticaldehydes and ketones, such as acetaldehyde, the keto form is thepredominant one; in phenols, the enol form is the major component.

Compounds of formula I which are basic can form pharmaceuticallyacceptable salts with inorganic acids such as hydrohalic acids (e.g.hydrochloric acid and hydrobromic acid), sulphuric acid, nitric acid andphosphoric acid, and the like, and with organic acids (e.g. with aceticacid, tartaric acid, succinic acid, fumaric acid, maleic acid, malicacid, salicylic acid, citric acid, methanesulphonic acid and p-toluenesulphonic acid, and the like). The formation and isolation of such saltscan be carried out according to methods known in the art.

Preferred is the use of compounds of formula I, wherein

R is hydrogen;

R¹ is alkyl, alkenyl, alkynyl, haloalkyl, alkylcarbonyl, alkoxy,hydroxymethyl, cyano, azido, alkoxyiminomethyl, alkylcarbonylamino,alkylaminomethyl or dialkylaminomethyl;

R² is hydrogen, hydroxy, alkoxy or halogen;

R³ and R⁴ are hydrogen, hydroxy, alkoxy, halogen or hydroxyalkyl,provided that at least one of R³ and R⁴ is hydrogen; or

R³ and R⁴ represent fluorine;

X is O or CH₂; and

B signifies a 9-purinyl residue B1 or a 1-pyrimidyl residue B2 asdefined above.

Examples of preferred compounds are listed below

Compound no. STRUCTURE Name  compound 6

4′-C- (Hydroxymethyl)cytidine  compound 7

5-Fluoro-4′-C-(hydroxymethyl)- uridine  compound 8

4′-C-Methoxyuridine compound 10

(E and/or Z)-4′-C-Azidouridine 4- oxime compound 11

4′-C-(Trifluoromethyl)cytidine compound 12

4′-C-(Trifluoromethyl)-5-methyl- cytidine compound 13

1-[4(S)-Azido-2(S),3(R)-dihydroxy- 4-(hydroxymethyl)-1(R)-cyclopentyl]cytosine compound 14

4′-C-(Hydroxy-methyl)adenosine compound 15

9-[4-C-(Hydroxymethyl)-beta-D- ribofuranosyl]-6-mercaptopurine compound16

4′-C-Azidoguanosine compound 17

2-Amino-4′-C-azidoadenosine compound 18

4′-C-Azidoadenosine compound 19

4′-C-(1-Propynyl)guanosine compound 20

2-Amino-4′-C-(1-propynyl)- adenosine compound 21

4′-C-(1-Propynyl)adenosine

An especially preferred group of compounds for the treatment of HCV arethose of formula I-b

wherein

R¹ is alkyl, alkenyl, alkynyl, haloalkyl, alkylcarbonyl, alkoxy,hydroxymethyl, cyano, azido, alkoxyiminomethyl, alkylcarbonylamino,alkylaminomethyl or dialkylaminomethyl;

R² is hydrogen, hydroxy, alkoxy, or halogen;

R³ and R⁴ are hydrogen, hydroxy, alkoxy, halogen or hydroxyalkyl,provided that at least one of R³ and R⁴ is hydrogen; or

R³ and R⁴ represent fluorine.

and pharmaceutically acceptable salts.

Examples of such especially preferred compounds are listed below

Compound no. Structure Name  compound 9

4′-C-Methoxycytidine compound 22

4′-C-(Fluoromethyl)cytidine compound 23

4′-C-Methylcytidine compound 24

4′-C-Azido-2′-deoxy-2′,2′- difluorocytidine compound 25

2′-Deoxy-4′-C-fluoro-2′,2′- difluorocytidine compound 26

2′-Deoxy-4′-C-ethynyl-2′,2′- difluorocytidine compound 27

4′-C-Azido-3′-O-methylcytidine compound 28

4′-C-Azido-3′-deoxycytidine compound 29

4′-C-Azido-3′-deoxy-3′- fluorocytidine compound 30

4′-C-(1-Propynyl)cytidine compound 31

4′-C-(1-Butynyl)cytidine compound 32

4′-C-Vinylcytidine compound 33

(E)-4′-C-(1-Propenyl)cytidine compound 34

(Z)-4′-C-(1-Propenyl)cytidine compound 35

4′-C-Ethylcytidine compound 36

4′-C-Propylcytidine compound 37

4′-C-Acetamidocytidine compound 38

(E)-4′-C-(Methoxyimino)cytidine compound 39

(E)-4′-C-(Ethoxyimino)cytidine compound 40

4′-C-[(Methylamino)methyl]- cytidine compound 41

4′-C- [(Ethylamino)methyl]cytidine compound 42

4′-C-[(Dimethylamino)methyl]- cytidine compound 43

4′-C-Azido-5-methylcytidine compound 44

4′-C-Azido-5-fluorocytidine compound 45

4′-C-Azido-5-hydroxycytidine

Most preferred compounds for the treatment of HCV are listed below:

Compound no. Structure Name compound 1 (Example 1)

4′-C-Azidocytidine compound 2 (Example 2)

4′-C-Cyanocytidine compound 3 (Example 3)

4′-C- Ethynylcytidine hydrochloride (1:1) compound 4

4′-C-Ethoxycytidine compound 5

4′-C-Acetylcytidine

The compounds of formula I may be prepared by various methods known inthe art of organic chemistry in general and nucleoside analoguesynthesis in particular. The starting materials for the syntheses areeither readily available from commercial sources or are known or maythemselves be prepared by techniques known in the art. General reviewsof the preparation of nucleoside analogues are included in the followingpublications:

A M Michelson “The Chemistry of Nucleosides and Nucleotides”, AcademicPress, New York 1963.

L Goodman “Basic Principles in Nucleic Acid Chemistry” Ed P O P Ts'O,Academic Press, New York 1974, Vol. 1, chapter 2.

“Synthetic Procedures in Nucleic acid Chemistry” Ed W W Zorbach and R STipson, Wiley, New York, 1973, Vol. 1 and 2.

The synthesis of carbocylic nucleosides has been reviewed by LAgrofoglio et al, Tetrahedron, 1994, 50, 10611.

The strategies available for the synthesis of compounds of formula Iinclude:

1. modification or interconversion of performed nucleosides; or

2. construction of the heterocyclic base after glycosylation; or

3. condensation of a protected furanose, thiofuranose or cyclopentanederivative with a pyrimidine (B2) or purine (B1) base.

These methods will be further discussed below:

1. Modification or inter-conversion of preformed nucleosides.

Such methods include on the one hand modification of the 9-purinyl or1-pyrimidyl residue or on the other hand modification of thecarbohydrate moiety.

A. Modification of the purinyl or pyrimidyl moiety:

a) The deamination of aminopurine or aminopyrimidine nucleosides asdescribed by J. R. Tittensor and R. T. Walker European Polymer J., 1968,4, 39 and H. Hayatsu, Progress in Nucleic Acid Research and MolecularBiology 1976, Vol. 16, p 75.

b) The conversion of the 4-hydroxy group of 4-hydroxypyrimidinenucleosides to a leaving group and displacement with nucleophilicreagents. Such leaving groups include halogen as described by J. Brokesand J. Beranek, Col. Czech. Chem. Comm., 1974, 39, 3100 or1,2,4-triazole as described by K. J. Divakar and C. B. Reece, J. Chem.Soc. Perkin Trans. I, 1982, 1171.

c) 5-Substitution of pyrimidine nucleosides has been achieved by the useof 5-metallo derivatives such as 5-mercuri or 5-palladium for example asdescribed by D. E. Bergstrom and J. L. Ruth J. Amer. Chem. Soc., 1976,98, 1587. Introduction of fluoro into the 5 position of pyrimidinenucleosides can be achieved with reagents such as trifluoromethylhypofluorite as described by M. J. Robins, Ann New York Acad. Sci. 1975,255, 104.

d) Modified purine nucleosides may be prepared from the correspondingpurine nucleoside derivatives wherein the 2, 6 or 8 substituent is asuitable leaving group such as halogen or sulphonate or 1,3,4-triazole.6 substituted purine nucleosides may be prepared by treatment of theappropriate 6-halopurine or 6-(1,2,4-triazol-4-yl)-purine nucleosidederivatives with the appropriate nucleophilic reagent as described by V.Nair and A. J. Fassbender Tetrahedron, 1993, 49, 2169 and by V. Samano,R. W. Miles and M. J. Robins, J. Am. Chem. Soc., 1994, 116, 9331.Similarly 8-substituted purine nucleosides can be prepared by treatmentof the corresponding 8-halopurine nucleoside with the appropriatenucleophilic reagent as described by L. Tai-Shun, C. Jia-Chong, I.Kimiko and A. C. Sartorelli, J. Med. Chem., 1985, 28, 1481; Nandanan etal, J. Med. Chem., 1999, 42, 1625; J. Jansons, Y. Maurinsh, and M.Lidaks, Nucleosides Nucleotides, 1995, 14, 1709. Introduction of an8-cyano substituent can be accomplished by displacement using a metalcyanide as described by L-L. Gundersen, Acta. Chem. Scand. 1996, 50, 58.2-Modified purine nucleoside may be prepared in a similar fashion asdescribed by T. Steinbrecher, C. Wamelung, F. Oesch and A. Seidl, Angew.Chem. Int. Ed. Engl., 1993, 32, 404.

e) Where the substituent at the 2 or 8-position of the purine nucleosideis linked via a carbon carbon bond e. g. alkyl, then metal catalysedcross-coupling procedures can be used starting with the appropriate 2 or8-halosubstituted purine nucleoside analogue as described by A. A. VanAerschott, et al, J. Med. Chem., 1993, 36, 2938; V. Nair and G. S.Buenger, J. Am. Chem. Soc., 1989, 111(22), 8502; C. Tu, C. Keane and B.E. Eaton Nucleosides Nucleotides, 1995, 14, 1631.

B. Modification of the carbohydrate moiety:

Following introduction of protecting groups which are compatible withthe further chemistry:

Azide may be introduced at the 4′-position by treatment of the4′,5′-didehydro nucleoside with iodine azide as exemplified by H. Maaget al, J. Med. Chem., 1992, 35, 1440. An alkoxide may be introduced atthe 4′-position by treatment of the 4′,5′-didehydro nucleoside withiodine followed by an alcohol and lead carbonate as exemplified by J. P.Verheyden and J. G. Moffatt, J. Am. Chem. Soc., 1975, 97(15), 4386.Fluoride may be introduced at the 4′-position by treatment of the4′,5′-didehydro nucleoside with iodine followed by silver(I)fluoride asdescribed by G. R. Owen et al, J. Org. Chem., 1976, 41(8), 3010 or A.Maguire et al, J. Chem. Soc. Perkin Trans. 1, 1993, 1(15), 1795. A4′-formyl group can be introduced and subsequently converted to a widerange of substituents including but not limited to 4′-haloalkyl,4′-ethynyl, 4′-oximinomethyl, and 4′-cyano as exemplified by M. Nomuraet al., J. Med. Chem., 1999, 42, 2901.

Modification of either the 2′-hydroxy substituent or 3′-hydroxysubstituent in the nucleoside analogue is possible.

Conversion of the 3-hydroxy to a leaving group such as halo by reactionwith for example triphenyl phosphine and a tetrahaloalkane as describedfor example by L. De Napoli et al, Nucleosides Nucleotides, 1993, 12,981, followed by reduction provides the 3-deoxysugar derivatives asdescribed by D. G. Norman and C. B. Reese, Synthesis 1983, 304.

Derivatisation of the 3 hydroxy group by conversion to a triflate groupfollowed by reduction using sodium borohydride as described by S. A.Surzhykov et al, Nucleosides Nucleotides, 1994, 13(10), 2283. Directintroduction of a fluorine substituent can be accomplished withfluorinating agents such as diethylaminosulphur trifluoride as describedby P. Herdewijn, A. Van Aerschot and L. Kerremans,NucleosidesNucleotides, 1989, 8, 65.

Conversion of the hydroxy substituent to a leaving group such as halo orsulphonate also allows displacement using nucleophilic reagents such astetrabutylammonium fluoride, lithium azide, or metal cyanides asexemplified by H. Hrebabecky, A. Holy and E. de Clercq, Collect. Czech.Chem. Comm. 1990, 55, 1800; K. E. B. Parkes and K. Taylor, Tet. Lett.,1988, 29, 2995; H. M. Pfundheller et al, Helv. Chim. Acta, 2000, 83,128.

Reaction of 2′-keto nucleosides with fluorinating agents such asdiethylamino sulfur trifluoride can be used to prepare2′,2′-difluoronucleosides as described by D. Bergstrom, E. Romo and P.Shum Nucleosides Nucleotides, 1987, 6, 53.

2. Construction of the heterocyclic base after glycosylation.

a) those which for example utilise furanosylamine derivatives asdescribed by N. J. Cusack, B. J. Hildick, D. H. Robinson, P. W. Rugg andG. Shaw J. Chem. Soc. Perkin Trans., I 1973, 1720 or G. Shaw, R. N.Warrener, M. H. Maguire and R. K. Ralph, J. Chem. Soc., 1958, 2294.

b) those which utilise for example furanosylureas for pyrimidinenucleoside synthesis as described by J. {hacek over (S)}mejkal, J.Farkas, and F. {hacek over (S)}orm, Coll. Czech. Chem. Comm., 1966, 31,291.

c) the preparation of purine nucleosides from imidazole nucleosides isreviewed by L. B. Townsend, Chem. Rev., 1967, 67, 533.

d) the preparation of compounds of formula I wherein X is CH₂ can beaccomplished from 1-hydroxymethyl-4-aminocyclopentane derivatives asdescribed by Y. F. Shealy and J. D. Clayton J. Am. Chem. Soc., 1969, 91,3075; R. Vince and S. Daluge J. Org. Chem., 1980, 45, 531; R. C. Cermakand R. Vince, Tet. Lett., 1981, 2331; R. D. Elliott et al, J. Med.Chem., 1994, 37, 739.

3. Condensation of a protected furanose, thiofuranose or cyclopentanederivative with a purine or pyrimidine derivative.

The condensation reaction of a protected furanose, thiofuranose orcyclopentane derivative with an appropriate purine or pyrimidinederivative may be performed using standard methods including the use ofa Lewis acid catalyst such as mercuric bromide or stannic chloride ortrimethylsilyltrifluoromethane sulphonate in solvents such asacetonitrile, 1,2-dichloroethane, dichloromethane, chloroform or tolueneat reduced, ambient or elevated temperature. Examples for thecondensation reaction of a protected furanose or thiofuranose

with heavy metal derivatives of purines or pyrimidines derivatives (e.g. chloromercuri derivatives) are described by J Davoll and B. A. Lowry,J. Am. Chem. Soc., 1951, 73, 1650; J. J. Fox, N. Yung, J. Davoll and G.B. Brown, J. Am. Chem. Soc., 1956, 78, 2117.

with alkoxy pyrimidines are described by K. A. Watanabe, D. H.Hollenberg and J. J. Fox., Carbohydrates. Nucleosides and Nucleotides.1974, 1,1.

with silyl derivatives of purines or pyrimidines as described by U.Niedballa and H. Vorbruggen, J. Org. Chem., 1976, 41, 2084; U. Niedballaand H. Vorbruggen, J. Org. Chem., 1974, 39, 3672. A. J. Hubbard, A. S.Jones and R. T. Walker, Nucleic Acids Res., 1984, 12, 6827.

Furthermore the fusion of per-acylated sugars with purines under vacuumin the presence of p-toluene sulphonic acid has been described by T.Simadate, Y. Ishudo and T. Sato, Chem. Abs., 1962, 56, 11 692 and W.Pfleiderer, R. K. Robins, Chem. Ber. 1965, 98, 1511.

the condensation reactions have been described by K. A. Watanabe, D. H.Hollenberg and J. J. Fox, Carbohydrates Nucleosides and Nucleotides,1974, 1,1.

Examples for the condensation reaction of a protected cyclopentanederivative with an appropriate purine derivative or pyrimidinederivative are given in H. Kapeller, H. Baumgartner and H. Griengl,Monattsh Chem., 1997, 128, 191 and P. Wang et al, Tet. Lett., 1997, 38,4207; or by T. Jenny et al. Helv. Chim. Acta, 1992, 25, 1944.

Such methods often result in mixtures of anomeric nucleoside derivativeswhich can be separated by standard techniques known to the art such asrecrystallisation, column chromatography, high performance liquidchromatography or super critical fluid chromatography.

The purine derivatives and pyrimidines derivatives for abovecondensation reactions can be obtained commercially or can be preparedby procedures known to the art.

The preparation of purine derivatives is reviewed by G. Shaw in“Comprehensive Heterocyclic Chemistry” pub Pergamon Press Vol. 5 chapter4. 09, p 499 and “Comprehensive Heterocyclic Chemistry II” publ.Pergamon Press, Vol 7, chapter 7. 11, p 397

The preparation of pyrimidines derivatives is reviewed by D. J. Brown in“The Chemistry of Heterocyclic Compounds—The Pyrimidines” 1962 andSupplement 1, 1970, pub John Wiley and Sons, New York, by D. J. Brown in“Comprehensive Heterocyclic Chemistry” pub Pergamon Press Vol. 5 chapter4. 09, p 499 and by K. Unheim and T. Benneche in “ComprehensiveHeterocyclic Chemistry II” pub Pergamon Press Vol. 6 chapter 6. 02 p 93

Furanose derivatives can be prepared from commercially availablecarbohydrate starting materials such as the D forms of ribose,arabinose, xylose or lyxose, following introduction of protecting groupswhich are compatible with the chemistry.

4-Substituted furanoses with the substituent containing a carbonattached to the 4-position of the furanose, for example alkyl, alkenyl,alkynyl, haloalkyl, acyl, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl,cyano, oximinomethyl, alkoxyiminomethyl, alkylaminocarbonyl and acyl canbe prepared from the corresponding 4-formyl furanose. The preparation ofone such 4-formylfuranose is described by H. Ohrui et al., J. Med.Chem., 2000, 43, 5416. 4-Haloalkyl furanoses may be prepared from thecorresponding 4-hydroxymethyl furanoses (e. g., K. Kitano et al,Tetrahedron, 1997, 53(39), 13315). 4-Methyl furanoses can be prepared bythe method described by T. Waga et al, Biosci. Biotech. Biochem. 1993,19(7), 408.

2,2-Difluorofuranose derivatives can be prepared from D-glucose orD-mannose as described by R. Fernandez, M. I. Mateu, R. Echarri and S.Castillon Tetrahedron, 1998, 54, 3523. The thiofuranose derivatives canbe prepared by literature procedures such as L. Bellon, J. L. Barascut,J. L. Imbach, Nucleosides and Nucleotides 1992, 11, 1467 and modified ina similar fashion to the furanose analogues described above.

The cyclopentane derivatives can be prepared by methods known in the artof organic chemistry and by methods and references included in L.Agrofolio et al, Tetrahedron, 1994, 50, 10611.

The preformed nucleoside derivatives are either available commerciallyor synthesised in accordance with the methods described above.

The methods discussed above are described in more details below:

The compounds of formula I, wherein R¹ is N₃, R² and R³ are hydroxy andB is B2 can be prepared according to Reaction Scheme A:

wherein Ac is acetyl, Bz is benzoyl and R¹¹ is as defined above.

Compounds of Formula II may be iodinated using a mixture oftriphenylphosphine, iodine and pyridine as exemplified by H. Maag et al,J. Med. Chem., 1992, 35, 1440. The acetonide protecting group can beremoved by treatment with an acid, for instance acetic acid, asdescribed by J. P. Verheyden et al, J. Org. Chem., 1970, 35(7), 2319, togive nucleosides of formula III. Following protection of the 2′ and 3′hydroxyls with acetic anhydride and pyridine elimination of hydrogeniodide, with for example silver fluoride in pyridine and removal of theacetyl protecting groups with methanolic ammonia as described by J. P.Verheyden et al., J. Org. Chem., 1974, 39(24), 3573, gives 4′,5′didehydro nucleosides of formula V. Addition of iodine azide to thedouble bond can be accomplished by treatment of V with a mixture ofiodine chloride and sodium azide in N,N-dimethylformamide as describedby H. Maag et al, J. Med. Chem., 1992, 35, 1440, to give nucleosides offormula VI. Protection of the hydroxy groups in VI can be accomplishedby treatment of VI with benzoyl chloride in pyridine, giving nucleosidesof formula VII, which can then be converted into the 5′-benzoylnucleosides of formula VIII by treatment with meta-chloroperbenzoic acidin dichloromethane, which can then be deprotected with a base, eg sodiummethoxide, in methanol to give nucleosides of formula IX, all asdescribed by H. Maag et al, J. Med. Chem., 1992, 35, 1440. In the casewhere B2 in the compound of formula VIII is uracil or 5′-substituteduracil, following protection of the 3′-hydroxy group with aceticanhydride and pyridine, conversion to the corresponding cytidine offormula XII can be accomplished by the method described by A. D.Borthwick et al., J. Med. Chem., 1990, 33(1), 179, whereby nucleosidesof formula X can be treated with 4-chlorophenyl dichlorophosphate andtriazole to give 4-triazolyl nucleosides of formula XI, followed bytreatment of nucleosides XI with aqueous ammonia giving 5-substitutedcytidines of formula XII.

Compounds of formula I, wherein R¹ is —C≡CH, —CH═CHCl, —CH═N—OH, —CN, R²and R³ are hydroxy and B is B1 or B2 can be prepared according toReaction Scheme B.

Compounds of formula XIII can be silylated withtert-butyldimethylsilylchloride (TBSCl) and imidazole to give thetri-tert-butyldimethylsilyl compounds of formula XIV. The5′-tert-butyldimethylsilyl ether can be deprotected using 80% aceticacid to give the 5-hydroxy nucleosides XV, which can then be oxidised tothe 5′-formyl nucleosides XVI using a mixture of1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDAC) anddimethylsulphoxide (DMSO) in a suitable solvent, eg benzene. Alkylationof XVI with formaldehyde and sodium hydroxide gives the 4′-hydroxymethylcompounds XVII which can be reduced to the 4′-dihydroxymethyl compoundsXVIII. Selective protection of the hydroxymethyl on the a face of thenucleoside with trityl chloride in pyridine gives the 4′-tritylcompounds XIX, followed by protection of the hydroxymethyl on the β-faceof the nucleoside with tert-butyldimethylsilylchloride (TBSCl) andimidazole gives compounds of formula XX. Deprotection of the tritylgroup with bromocatecholborane gives the 4′-hydroxymethyl compound XXI,which can be oxidised with trifluoromethanesulphonic anhydride anddimethylsulphoxide to give the 4′-formyl compound of formula XXII.

The aldehyde of formula XXII can be used as starting material for a widerange of 4′-substituted nucleosides as depicted in Scheme C:

Treatment of the aldehyde XXII with hydroxylamine hydrochloride andpyridine gives the 4′-hydroxyimine of formula XXIII. Water is eliminatedfrom compound XXIII to give 4′-cyano compounds of formula XXIV.Treatment of 4′-formyl compounds of formula XXII withchloromethyl-phosphonium chloride and butyl lithium gives the4′-(2-chloroethenyl) compounds XXVI. Treatment of compounds XXVI withbutyllithium results in the elimination of hydrogen chloride to give the4′-ethynyl compounds of formula XXVII. Removal of the silyl protectinggroups from the tri tert-butyldimethylsilylchloride protected compoundsXXIII, XXVII and XXIV can be carried out with a fluoride source such asammonium fluoride in methanol or tetrabutylammonium fluoride absorbed onsilica in tetrahydrofuran, to give the respective 4′-substitutednucleosides XXV, XXVIII and XXIX.

Suitably protected 4′-substituted uridines (for example XXIV and XXVII)can be converted to the corresponding 4′-substituted cytidines accordingto Reaction Scheme D.

The tri-tertbutyldimethylsilyl (TBS) protected uridines of formula XXXcan be treated with tri-isopropylbenzenesulphonyl chloride,triethylamine and dimethylaminopyridine to give the4-triazolylnucleosides XXXI. The 4-triazolyl compounds XXXI can beconverted to the 4-amino compounds XXXII with aqueous ammonia.Deprotection of the silyl groups with a mixture of methanol andhydrochloric acid in dioxan gives the cytidine derivatives XXXIII.

Compounds of formula I, wherein R¹ is alkoxy, R² and R³ are hydroxy andB is a 9-purinyl residue B1 or a 1-pyrimidyl residue B2 can be preparedaccording to the procedures described by J. P. Verheyden et al. U.S.Pat. No. 3,910,885

Compounds of formula I in which R¹ is trifluoromethyl, methyl or ethynylcan be prepared as depicted in Reaction Scheme E:

for example by coupling the appropriate protected 4′-substitutedribofuranoside XXXIV with a silylated base in the presence of a Lewisacid, eg trimethylsilyltrifluoromethanesulphonate (TMSOTf) or tintetrachloride, in an appropriate solvent, eg acetonitrile or1,2-dichloroethane, to give compound of formula XXXV. The protectinggroups can be removed by treatment of XXXV with a base, for examplesodium methoxide, in compatible solvent for instance methanol to givecompounds of formula XXXVI.

Methods for the monophosphorylation of organic compounds includingnucleosides have been reviewed by L A Slotin, Synthesis, 1977, 737. Morerecently other nucleoside phosphorylation procedures have beendescribed: M Uchiyama et al J. Org. Chem., 1993, 58,373; R Caputo et al,Synlett., 1997, 739 and M Taktakishvili and V Nair Tet. Lett. 2000, 41,7173. Other procedures for monophosphorylation that may be useful fornucleosides are described by C E McKenna and J Schmidhauser, J. Chem.Soc., Chem. Commun., 1979, 739 and J K Stowell and T S Widlanski Tet.Lett., 1995, 1825. Synthesis of di and triphosphate derivatives arereviewed in K H Scheit, Nucleotide Analogues, 1980, Wiley Interscienceand by K Burgess and D Cook Chemical Reviews, 2000, 100, 2047.

The following Examples illustrate methods for the preparation ofcompounds of formula I:

EXAMPLE 1

Preparation of compound 1, according to the method of schemes 1 and 1a

1.1. Compound (i)

Compound (i) was purchased from Lancaster (Cat. no.: 206-647-7, CAS362-43-6)

1.2. Compound (ii)

Triphenylphosphine (1.57 g, 6.0 mmol) and iodine (1.52 g, 6.0 mmol) wereadded to compound (i) (1.14 g, 4.0 mmol) in dioxan (20 ml) containingpyridine (0.65 mmol, 8.0 mmol). The mixture was stirred overnight andquenched with methanol (1 ml). The solvent was evaporated in vacuo. Theresidue was dissolved in ethyl acetate (200 ml), washed with water (100ml), 10% aqueous sodium thiosulphate (100 ml), brine (100 ml) and driedover anhydrous magnesium sulphate. The magnesium sulphate was removed byfiltration and the filtrate evaporated in vacuo. The residue waspurified by flash column chromatography on silica gel, eluting with 1:1ethyl acetate/petrol) to afford compound (ii) as a colourless oil whichslowly solidified to a colourless waxy solid (1.5 g) mass spectrum (CI)m/z 395 [M+H]⁺.

1.3. Compound (iii)

Compound (iii) was prepared from compound (ii) as described by J. P.Verheyden et al., J. Org. Chem., 1970, 35(7), 2319.

1.4. Compound (iv)

Compound (iv) was prepared from compound (iii) as described by J. P.Verheyden et al., J. Org. Chem., 1974, 39(24), 3573.

1.5. Compound (v)

Compound (v) was prepared from compound (iv) as described by H. Maag etal., J. Med. Chem., 1992, 35, 1440-1451.

1.6. Compound (vi)

To a solution of compound (v) (482 mg, 0.80 mmol) in dichloromethanesaturated with water (10 ml) was added 55% metachloroperbenzoic acid(1.0 g, 4.95 mmol). The mixture was stirred for 2 h. Additionalmetachloroperbenzoic acid (0.50 g) was added and the mixture was stirredfor an additional 3 h. Ethyl acetate (100 ml) was added and the solutionwashed with 10% sodium metabisulphite solution (50 ml), followed bysaturated sodium hydrogen carbonate solution (50 ml). The ethyl acetatewas dried over anhydrous magnesium sulphate. The magnesium sulphate wasremoved by filtration and the filtrate was evaporated in vacuo. Theresidue was subjected to flash chromatography, eluting with 1:1 ethylacetate/petrol 1:1 to afford compound (vi) as a colourless glass (200mg); mass spectrum (ESI) m/z 535 [M+H+CH₃CN]⁺

1.7. Compound (vii)

To a solution of compound (vi) (170 mg, 0.35 mmol) in methanol (2 ml)was added a solution of sodium methoxide in methanol (0.5 M, 0.5 ml).The solution was stirred for 2 h at room temperature. The solution wasneutralised with ion exchange resin (Amberlite IRC 50 (H⁺), Aldrich,cat. no. 42,883-3) and stirred for 10 min. The resin was removed byfiltration. The filtrate was evaporated in vacuo and the residue wassubjected to flash chromatography eluting with 1:1 ethylacetate/acetone) to afford a colourless oil. Trituration with ethylacetate afforded compound (vii) as a colourless solid (35 mg); massspectrum (CI) m/z 286 [M+H]⁺.

The transformation of the azidouridine derivative to the correspondingazidocytidine derivative (compound 1) and its hydrochloride salt isdepicted in Scheme 1a

1.8. Compound (viii)

To a solution of compound (vi) (460 mg, 0.93 mmol) in pyridine (3 ml)was added acetic anhydride (1 ml) and the mixture was stirred for 4 h.Ethyl acetate (100 ml) was added and the mixture was washed with 2 N HCl(50 ml), followed by saturated sodium hydrogen carbonate solution (50ml). The solution was dried over anhydrous magnesium sulphate. Themagnesium sulphate was removed by filtration and the filtrate wasevaporated in vacuo. The residue was subjected to flash chromatographyeluting with 1:1 ethyl acetate/petrol to afford compound (viii) as acolourless gum (350 mg); mass spectrum (ESI) m/z 536 [M+H]⁺

1.9. Compound 1

To a solution of compound (viii) (1.5 g, 2.8 mmol) in pyridine (20 ml)was added 1,2,4-triazole (0.97 g, 14 mmol).4-chlorophenyldichlorophosphate (1.36 ml, 8.4 mmol) was then addeddropwise with stirring. The mixture was stirred for 16 h. Ethyl acetate(300 ml) was added and the mixture was washed with saturated sodiumhydrogen carbonate solution (200 ml). The solution was dried overanhydrous magnesium sulphate. The magnesium sulphate was removed byfiltration and the filtrate was evaporated in vacuo. The residue wassubjected to flash chromatography eluting with 2:1 ethyl acetate/petrolto afford a yellow foam (850 mg). The foam was treated with dioxan (8ml) followed by aqueous ammonia solution (16 ml) and stirred for 16 h.The filtrate was evaporated in vacuo and the residue was subjected toflash chromatography eluting with 90:18:3:2dichloromethane/methanol/acetic acid/water to afford compound 1 as alight tan foam (350 mg); mass spectrum (FAB) m/z 285 [M+H]⁺

1.10. Hydrochloride of Compound 1

Compound 1 (0.40 g) was dissolved in methanol and treated with asolution of hydrogen chloride in ethyl acetate. The product separated asa microcrystalline solid and was collected by filtration and dried invacuo to afford the hydrochloride salt of compound 1 (0.22 g); massspectrum (ESI) m/z 285 [M+H]⁺

EXAMPLE 2

Preparation of compound 2 according to the method of scheme 2

2.1. Compound (ix)

Compound (ix) was prepared from compound (xiv), see example 3, asdescribed by M. Nomura et al., J. Med. Chem., 1999, 42, 2901-2908.

2.2. Compound (x)

A mixture of (ix) (600 mg, 0.98 mmol) and hydroxylamine hydrochloride(140 mg, 1.95 mmol) in pyridine was stirred at room temperature for 2 h.The reaction mixture was evaporated in vacuo and the residue waspartitioned between ethyl acetate (30 ml) and water (30 ml). The ethylacetate layer was separated and dried over anhydrous magnesium sulphate.The magnesium sulphate was removed by filtration and the filtrateevaporated in vacuo to afford compound (x) as a white foam (615 mg);mass spectrum (ESI) m/z 630 {M+H]⁺.

2.3. Compound (xi)

A mixture of compound (x) (550 mg, 0.87 mmol) and sodium acetate (720mg, 5.25 mmol) was suspended in acetic anhydride then heated at 130° C.for 3 h. The reaction mixture was evaporated in vacuo and the residuepartitioned between ethyl acetate (30 ml) and saturated sodiumbicarbonate (30 ml). The ethyl acetate layer was separated and driedover anhydrous magnesium sulphate. The magnesium sulphate was removed byfiltration and the filtrate evaporated in vacuo. The residue waspurified by flash column chromatography on silica gel, eluting with 1:2diethyl ether/hexane. Product containing fractions were combined andevaporated in vacuo to afford compound (xi) as a colourless solid (285mg). mass spectrum (ESI) m/z 612 [M+H]⁺.

2.4. Compound (xii)

4-chlorophenyl-dichlorophosphate (160 μL, 0.98 mmol) was added dropwiseto a solution of compound (xi) (200 mg, 0.33 mmol) and 1,2,4-triazole(115 mg, 1.63 mmol) in anhydrous pyridine (5 ml) then stirred at roomtemperature for 16 h. The reaction mixture was evaporated in vacuo andthe residue partitioned between ethyl acetate (30 ml) and 2Mhydrochloric acid (30 ml). The ethyl acetate layer was separated, washedwith saturated sodium bicarbonate (30 ml) and dried over anhydrousmagnesium sulphate. The magnesium sulphate was removed by filtration andthe filtrate evaporated in vacuo. The residue was purified by flashcolumn chromatography on silica gel, eluting with 1:1 diethylether/hexane followed by 2:1 diethyl ether/hexane. Product containingfractions were combined and evaporated in vacuo to afford (xii) as acream solid (65 mg). mass spectrum (ESI) m/z 663 [M+H]⁺.

2.5. Compound (xiii)

A solution of compound (xii) (60 mg, 0.09 mmol) and aqueous ammonia (2ml) in acetonitrile was stirred at room temperature for 16 h. Thereaction mixture was evaporated in vacuo and the residue partitionedbetween ethyl acetate (10 ml) and 2 M hydrochloric acid (10 ml). Theethyl acetate layer was separated and dried over magnesium sulphate. Themagnesium sulphate was removed by filtration and evaporated in vacuo toafford compound (xiii) as a pale yellow solid (45 mg); mass spectrum(ESI) m/z 611 [M+H]⁺

2.6. Compound 2

Tetrabutylammonium fluoride (1 M solution in THF, 0.3 ml) was added to astirred solution of compound (xiii) (40 mg, 0.06 mmol) in drytetrahydrofuran (10 ml) and stirred at room temperature for 2 h. Thesolvent was removed by evaporation in vacuo The residue was treated withpyridine (1 ml) followed by acetic anhydride (0.3 ml) and stirred for 4h at room temperature. The solvent was removed by evaporation in vacuo.The residue was treated with ethyl acetate (50 ml) and washed withdilute hydrochloric acid (30 ml) followed by a 5% aqueous sodiumbicarbonate solution. The ethyl acetate was dried over anhydrousmagnesium sulphate. The magnesium sulphate was removed by filtration andthe filtrate evaporated in vacuo. The residue was subjected to flashcolumn chromatography eluting with ethyl acetate to afford an oil. Theoil was dissolved in methanol (1 ml) and treated with sodium methoxide(0.5M solution in methanol, 0.05 ml) and stood at room temperature for 3h. The mixture was neutralised with ion exchange resin (Amberlite IRC 50(H⁺). The resin was removed by filtration, and the filtrate evaporatedin vacuo. The residue was dissolved in water and freeze dried to affordcompound 2 as an amorphous solid (7 mg).

2.7. The corresponding 4′-cyanouridine can be prepared by deprotectionof compound (xi).

The deprotection can be carried out as follows:

Compound (xi) (50 mg, 82 μmol) was dissolved in tetrahydrofuran, treatedwith tetrabutylammonium fluoride on silica then stirred for 16 h at roomtemperature. The reaction mixture was filtered through Hyflo Super Cel(Fluka, cat no. 56678), evaporated in vacuo, then purified by flashcolumn chromatography on silica gel, eluting withdichloromethane/methanol/acetic acid/water (240:24:3:2) followed bydichloromethane/methanol/acetic acid/water (90:18:3:2). Productcontaining fractions were combined and evaporated. The residue wasdissolved in methanol/water (5:1), treated with Duolite C225 ionexchange resin (H⁺ form, BDH, cat. no. 56678) and stirred for 15 min.The resin was removed by filtration and the filtrate evaporated in vacuoto low volume. The product was collected by filtration and dried invacuo to afford 4′-cyanouridine as a white crystalline solid (15 mg);mass spectrum m/z (ESI) 270 [M+H]⁺.

EXAMPLE 3

Preparation of compound 3 according to the method of Scheme 3

3.1. Compound (xiv)

This compound was prepared as described by M. Nomura et al., J. Med.Chem., 1999, 42, 2901-2908.

3.2. Compound (xv)

Trityl chloride (3.2 g; 11.5 mmol) was added to a solution of compound(xiv) (3.0 g, 6.0 mmol) in pyridine (20 ml) and stirred at roomtemperature for 16 h. The solvent was evaporated in vacuo and theresidue partitioned between ethyl acetate (50 ml) and 2 M hydrochloricacid (50 ml). The ethyl acetate layer was separated, washed with brine(50 ml) and dried over anhydrous magnesium sulphate. The magnesiumsulphate was removed by filtration and the filtrate evaporated in vacuo.The crude material was purified by flash column chromatography on silicagel, eluting with 2:1 diethyl ether/hexane. Product containing fractionswere combined and evaporated in vacuo to afford compound (xv) as a whitesolid (2.75 g); mass spectrum (ESI) m/z 767 [M+H]⁺.

3.3. Compound (xvi)

tert-Butyldimethylsilylchloride (0.67 g, 4.4 mmol) and imidazole (0.91g, 13.3 mmol) was added to a stirred solution of compound (xv) (2.75 g,3.7 mmol) in dimethylformamide (20 ml). The reaction was heated to 45°C. for 16 h. Additional tert-butyldimethylsilylchloride (0.67 g, 4.4mmol) and imidazole (0.91 g, 13.3 mmol) were added and the mixture washeated to 60° C. for 4 h. The solvent was removed by evaporation invacuo and the residue was partitioned between ethyl acetate and brine.The ethyl acetate was separated and washed with more brine and driedover anhydrous magnesium sulphate. The magnesium sulphate was removed byfiltration and the filtrate evaporated in vacuo. The residual colourlessfoam was purified by flash column chromatography on silica gel, elutingwith 1:2 diethyl ether/hexane. Product containing fractions werecombined and evaporated in vacuo to afford compound (xvi) as a whitesolid (3.1 g).

3.4. Compound (xvii)

Bromocatecholborane (355 mg, 1.77 mmol) was added to a stirred solutionof compound (xvi) (1.5 g, 1.77 mmol) in dry dichloromethane (50 ml),under a nitrogen atmosphere at 0° C. The reaction was stirred for 15min, diluted with dichloromethane (50 ml) then washed with saturatedsodium bicarbonate (100 ml) and brine (100 ml). The dichloromethane wasdried over anhydrous magnesium sulphate. The magnesium sulphate wasremoved by filtration and the filtrate evaporated in vacuo. The residuewas purified by flash column chromatography on silica gel, eluting with1:1 diethyl ether/hexane. Product containing fractions were combined andevaporated in vacuo to afford compound (xvii) as a white solid (930 mg).

3.5. Compound 3

was prepared from compound (xvii) as described by M. Nomura et al., J.Med. Chem., 1999, 42, 2901-2908.

Further compounds can be prepared according to the methods described inthe art, for example:

Compound no. Structure Name and preparation method  compound 6

4′-C-(Hydroxymethyl)cytidine G. H. Jones et al., J. Org. Chem., 1979,44(8), 1309.  compound 7

5-Fluoro-4′-C-(hydroxymethyl)uridine Youssefyeh et al., J. Org. Chem.,1979, 44, 1301.  compound 8

4′-C-Methoxyuridine J. A. Cook and J. L. Secrist, J. Am. Chem. Soc.,1979, 101, 1554  compound 9

4′-C-Methoxycytidine J. G. Moffatt and J. P. Verheyden, U.S. Pat. No.3,910,885 compound 22

4′-C-(Fluoromethyl)cytidine K. Kitano et al., Tetrahedron, 1997, 53(39),13315. compound 23

4′-C-Methylcytidine T. Waga et al., J. Biosci. Biotechnol. Biochem.,1993, 57(9), 1433

Additional compounds of formula I can be prepared in analogy to themethods described in the prior art listed below:

4′-C-Allyluridine J. Secrist et al., J. Am. Chem. Soc., 1978, 100, 2554.

9-[4-C-(Hydroxymethyl)-beta-D- ribofuranosyl]-6-mercaptopurineYoussefyeh et al., J. Org. Chem., 1979, 44, 1301

4′-C-(Hydroxymethyl)adenosine A. Rosenthal and M. Ratcliffe, Carbohydr.Res., 1977, 54, 61.

4′-C-(Trifluoromethyl)-5- methyluridine J. Kozak and C. R. Johnson 1998,17(12), 2221.

4′-C-(Ethynyl)-5-methyluridine R. Yamaguchi et al., J. Biosci.Biotechnol. Biochem., 1999, 63(4), 736

4′-C-Methoxyadenosine C. M. Richards et al., Carbohydr. Res., 1982, 100,315.

1-[4-C-(Hydroxymethyl)-beta- D-xylofuranosyl]uracil G. H. Jones et al.,J. Org. Chem., 1979, 44(8), 1309-1317

1-[4-C-(Hydroxymethyl)-beta- D-arabinofuranosyl]cytosine T. Waga et al.,Nucleosides Nucleotides, 1996, 15(1-3) 287-304

4′-C-(Hydroxymethyl)guanosine J. C. Martin and J. P. Verheyden,Nucleosides Nucleotides 1988, 7(3), 365

9-[4-C-(Hydroxymethyl)-beta- D-xylofuranosyl]adenine D. L. Leland and M.P. Kotick, Carbohydr. Res., 1974, 38, C9-C11

3′-Azido-3′-deoxy-4′-C- (hydroxymethyl)-5- methyluridine A. G. Olsen etal, J. Chem. Soc. Perkin Trans. 1, 2000, 21, 3610

1-(4-C-Ethynyl-beta-D- arabinofuranosyl)cytosine H. Ohrui et al, J. Med.Chem., 2000, 43(23), 4516 or S. Kohgo et al., Biosci. Biotechnol.Biochem., 1999, 63(6), 1146

N4-Benzoyl-1-[4-C-methyl-beta- D-arabinofuranosyl]cytosine T. Yamaguchiet al., Nucleosides Nucleotides, 1997, 16(7), 1347

3′-Azido-3′-deoxy-4′-C- (hydroxymethyl)uridine S. A. Surzhikov and N. B.Dyatkina Russ. J. Biorg. Chem. (Engl. Transl.), 1993, 19(7), 408

The following assay method demonstrates the ability of the compounds offormula I to inhibit HCV RNA replication, and therefore their potentialutility for the treatment of HCV infections.

Renilla Luciferase Assay

This assay is based on the idea of using a reporter as a simple readoutfor intracellular HCV replicon RNA level. For this purpose Renillaluciferase gene was introduced into the first open reading frame of areplicon construct NK5.1 (Krieger et al., J. Virol. 75:4614),immediately after the internal ribosome entry site (IRES) sequence, andfused with the neomycin phosphotransferase (NPTII) gene via aself-cleavage peptide 2A from foot and mouth disease virus (Ryan & Drew,EMBO Vol 13:928-933). After in vitro transcription the RNA waselectroporated into human hepatoma Huh7 cells, and G418-resistantcolonies were isolated and expanded. Stably selected cell line 2209-23was shown to contain replicative HCV subgenomic RNA, and the activity ofRenilla luciferase expressed by the replicon reflects its RNA level inthe cells.

For the assay procedure, Renilla Luciferase HCV replicon cells (2209-23)that cultured in Dulbecco's MEM (GibcoBRL cat no. 31966-021) with 5%fetal calf serum (FCS, GibcoBRL cat. no. 10106-169) were plated onto a96-well plate at 5000 cells per well, and incubated overnight.Twenty-four hours later, different dilutions of chemical compounds inthe growth medium were added to the cells, which were then furtherincubated at 37° C. for three days. The assay was carried out induplicate plates, one in opaque white and one in transparent, in orderto measure the activity and cytotoxicity of a chemical compound inparallel ensuring the activity seen is not due to reduction on cellproliferation.

At the end of the incubation time, the cells in white plates wereharvested and luciferase activity was measured by using Dual-Luciferasereporter assay system (Promega cat no. E1960) All the reagents describedin the following paragraph were included in the manufacturers kit, andthe manufacturer's instructions were followed for preparations of thereagents. Briefly, the cells were washed twice with 200 μl phosphatebuffered saline (pH 7.0) (PBS) per well and lysed with 25 μl of 1×passive lysis buffer prior to incubation at room temperature for 20 min.One hundred microlitre of LAR II reagent was added to each well. Theplate was then inserted into the LB 96V microplate luminometer(MicroLumatPlus, Berthold), and 100 μl of Stop & Glo reagent wasinjected into each well by the machine and the signal measured using a2-second delay, 10-second measurement program. IC50, the concentrationof the drug required for reducing replicon level by 50% in relation tothe untreated cell control value, can be calculated from the plot ofpercentage reduction of the luciferase activity vs. drug concentration.The results are compiled below.

For the cytotoxicity assay, WST-1 reagent from Roche Diagnostic (cat no.1644807) was used. Ten microlitre of WST-1 reagent was added to eachwell including wells that contain media alone as blanks. Cells were thenincubated for 1 to 1.5 hours at 37° C., and the OD value was measured bya 96-well plate reader at 450 nm (reference filter at 650 nm). AgainCC50, the concentration of the drug required for reducing cellproliferation by 50% in relation to the untreated cell control value,can be calculated from the plot of percentage reduction of the WST-1value vs. drug concentration.

Compound IC50 CC50(μM) no. STRUCTURE Name (μM) WST-1 compound 1

4′-C-Azidocytidine 1.2 0% (100 μM) compound 3

4′-C-Ethynylcytidine hydrochloride (1:1) 3% (20 μM) 0% (20 μM)

As shown in above Table the compounds of formula I have the potential tobe efficacious as antiviral drugs for the treatment of HCV infections inhumans, or are metabolized to a compound that exhibit such activity.

In another embodiment of the invention, the active compound or itsderivative or salt can be administered in combination with anotherantiviral agent, such as an anti-hepatitis agent, including those offormula I. When the active compound or its derivative or salt areadministered in combination with another antiviral agent the activitymay be increased over the parent compound. This can easily be assessedby preparing the derivative and testing its anti-HCV activity accordingto the method described herein.

Administration of the active compound may range from continuous(intravenous drip) to several oral administrations per day (for example,Q.I.D) and may include oral, topical parenteral, intramuscular,intravenous, subcutaneous, transdermal (which may include a penetrationenhancement agent), buccal and suppository administration, among otherroutes of administration.

The 4′-substituted nucleoside derivatives as well as theirpharmaceutically usable salts, can be used as medicaments in the form ofany pharmaceutical formulation. The pharmaceutical formulation can beadministered enterally, either orally, e.g. in the form of tablets,coated tablets, dragees, hard and soft gelatine capsules, solutions,emulsions, syrups, or suspensions, or rectally, e.g. in the form ofsuppositories. They can also be administered parenterally(intramuscularly, intravenously, subcutaneously or intrasternalinjection or infusion techniques), e.g. in the form of injectionsolutions, nasally, e.g. in the form of nasal sprays, or inhalationspray, topically and so forth.

For the manufacture of pharmaceutical preparations, the 4′-substitutednucleoside derivatives, as well as their pharmaceutically usable salts,can be formulated with a therapeutically inert, inorganic or organicexcipient for the production of tablets, coated tablets, dragees, hardand soft gelatine capsules, solutions, emulsions or suspensions.

The compounds of formula I can be formulated in admixture with apharmaceutically acceptable carrier. For example, the compounds of thepresent invention can be administered orally as pharmacologicallyacceptable salts. Because the compounds of the present invention aremostly water soluble, they can be administered intravenously inphysiological saline solution (e.g., buffered to a pH of about 7.2 to7.5). Conventional buffers such as phosphates, bicarbonates or citratescan be used for this purpose. Of course, one of ordinary skill in theart may modify the formulations within the teachings of thespecification to provide numerous formulations for a particular route ofadministration without rendering the compositions of the presentinvention unstable or compromising their therapeutic activity. Inparticular, the modification of the present compounds to render themmore soluble in water or other vehicle, for example, may be easilyaccomplished by minor modifications (salt formulation, esterification,etc.) which are well within the ordinary skill in the art. It is alsowell within the ordinary skill of the art to modify the route ofadministration and dosage regimen of a particular compound in order tomanage the pharmacokinetics of the present compounds for maximumbeneficial effect in patients.

For parenteral formulations, the carrier will usually comprise sterilewater or aqueous sodium chloride solution, though other ingredientsincluding those which aid dispersion may be included. Of course, wheresterile water is to be used and maintained as sterile, the compositionsand carriers must also be sterilized. Injectable suspensions may also beprepared, in which case appropriate liquid carriers, suspending agentsand the like may be employed.

Suitable excipients for tablets, coated tablets, dragees, and hardgelatin capsules are, for example, lactose, corn starch and derivativesthereof, talc, and stearic acid or its salts.

If desired, the tablets or capsules may be enteric-coated or sustainedrelease by standard techniques.

Suitable excipients for soft gelatine capsules are, for example,vegetable oils, waxes, fats, semi-solid and liquid polyols.

Suitable excipients for injection solutions are, for example, water,saline, alcohols, polyols, glycerine or vegetable oils.

Suitable excipients for suppositories are, for example, natural andhardened oils, waxes, fats, semi-liquid or liquid polyols.

Suitable excipients for solutions and syrups for enteral use are, forexample, water, polyols, saccharose, invert sugar and glucose.

The pharmaceutical preparations of the present invention may also beprovided as sustained release formulations or other appropriateformulations.

The pharmaceutical preparations can also contain preservatives,solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners,colorants, flavourants, salts for adjustment of the osmotic pressure,buffers, masking agents or antioxidants.

The pharmaceutical preparations may also contain other therapeuticallyactive agents known in the art.

The dosage can vary within wide limits and will, of course, be adjustedto the individual requirements in each particular case. For oraladministration, a daily dosage of between about 0.01 and about 100 mg/kgbody weight per day should be appropriate in monotherapy and/or incombination therapy. A preferred daily dosage is between about 0.1 andabout 500 mg/kg body weight, more preferred 0.1 and about 100 mg/kg bodyweight and most preferred 1.0 and about 100 mg/kg body weight per day. Atypical preparation will contain from about 5% to about 95% activecompound (w/w). The daily dosage can be administered as a single dosageor in divided dosages, typically between 1 and 5 dosages per day.

In certain pharmaceutical dosage forms, the pro-drug form of thecompounds, especially including acylated (acetylated or other)derivatives, pyridine esters and various salt forms of the presentcompounds are preferred. One of ordinary skill in the art will recognisehow to readily modify the present compounds to pro-drug forms tofacilitate delivery of active compounds to a target site within the hostorganism or patient. One of ordinary skill in the art will also takeadvantage of favourable pharmacokinetic parameters of the pro-drugforms, where applicable, in delivering the present compounds to targetedsite within the host organism or patient to maximise the intended effectof the compound.

The nucleoside derivatives or the medicaments thereof may be used inmonotherapy or combination therapy, i.e. the treatment may be inconjunction with the administration of one or more additionaltherapeutically active substance(s), for example, an immune systemmodulator such as an interferon, interleukin, tumor necrosis factor orcolony stimulating factor; an antiviral agent or an anti-inflammatoryagent. When the treatment is combination therapy, such administrationmay be concurrent or sequential with respect to that of the4′-substituted nucleoside derivatives. Concurrent administration, asused herein thus includes administration of the agents at the same timeor at different times.

It will be understood that references herein to treatment extend toprophylaxis as well as to the treatment of existing conditions, and thatthe treatment of animals includes the treatment of humans as well asother mammals. Furthermore, treatment of an Hepatitis C Virus (HCV)infection, as used herein, also includes treatment or prophylaxis of adisease or a condition associated with or mediated by Hepatitis C Virus(HCV) infection, or the clinical symptoms thereof.

The features disclosed in the foregoing description, or the followingclaims, or the accompanying drawings, expressed in their specific formsor in terms of a means for performing the disclosed function, or amethod or process for attaining the disclosed result, as appropriate,may, separately, or in any combination of such features, be utilised forrealising the invention in diverse forms thereof.

The foregoing invention has been described in some detail by way ofillustration and example, for purposes of clarity and understanding. Itwill be obvious to one of skill in the art that changes andmodifications may be practiced within the scope of the appended claims.Therefore, it is to be understood that the above description is intendedto be illustrative and not restrictive. The scope of the inventionshould, therefore, be determined not with reference to the abovedescription, but should instead be determined with reference to thefollowing appended claims, along with the full scope of equivalents towhich such claims are entitled.

All patents, patent applications and publications cited in thisapplication are hereby incorporated by reference in their entirety forall purposes to the same extent as if each individual patent, patentapplication or publication were so individually denoted.

1. A method of treating a disease mediated by the HCV virus comprisingadministering to a patient in need thereof an effective amount of acompound of formula I

wherein R is hydrogen or —[P(O)(OH)—O]_(n)H and n is 1, 2 or 3; IV isalkyl, alkenyl, alkynyl, haloalkyl, alkylcarbonyl, alkoxycarbonyl,hydroxyalkyl, alkoxyalkyl, alkoxy, cyano, azido, hydroxyiminomethyl,alkoxyiminomethyl, halogen, alkylcarbonylamino, alkylaminocarbonyl,azidoalkyl or aminomethyl, alkylaminomethyl, dialkylaminomethyl orheterocyclyl; R² is hydrogen, hydroxy, amino, alkyl, hydroxyalkyl,alkoxy, halogen, cyano, or azido; R³ and R⁴ are hydrogen, hydroxy,alkoxy, halogen or hydroxyalkyl, provided that at least one of R³ and R⁴is hydrogen; or R³ and R⁴ together represent ═CH₂ or ═N—OH, or R³ and R⁴both represent fluorine; X is O, S or CH₂; B signifies a 9-purinylresidue B1 of formula

wherein R⁵ is hydrogen, hydroxy, alkyl, alkoxy, alkylthio, NHR⁸, halogenor SH; R⁶ is hydroxy, NHR⁸, NHOR⁹, NHNR⁸, —NHC(O)OR^(9′) or SH; R⁷ ishydrogen, hydroxy, alkyl, alkoxy, alkylthio, NHR⁸, halogen, SH or cyano;R⁸ is hydrogen, alkyl, hydroxyalkyl, arylcarbonyl or alkylcarbonyl; R⁹is hydrogen or alkyl; R^(9′) is alkyl; or B signifies a 1-pyrimidylresidue B2 of formula

wherein Z is O or S; R¹⁰ is hydroxy, NHR⁸, NHOR⁹, NHNR⁸, —NHC(O)OR^(9′)or SH; R¹¹ is hydrogen, alkyl, hydroxy, hydroxyalkyl, alkoxyalkyl,haloalkyl or halogen; R⁸ R⁹ and R^(9′) are as defined above; and ofpharmaceutically acceptable salts thereof.
 2. The method of claim 1wherein R is hydrogen; R¹ is alkyl, alkenyl, alkynyl, haloalkyl,alkylcarbonyl, alkoxy, hydroxymethyl, cyano, azido, alkoxyiminomethyl,alkylcarbonylamino, alkylaminomethyl or dialkylaminomethyl; R² ishydrogen, hydroxy, alkoxy, or halogen; R³ and R⁴ are hydrogen, hydroxy,alkoxy, halogen or hydroxyalkyl, provided that at least one of R³ and R⁴is hydrogen; or R³ and R⁴ represent fluorine; X is O or CH₂; and Bsignifies a 9-purinyl residue B1 or a 1-pyrimidyl residue B2 as inclaim
 1. 3. The method of or claim 2 wherein the compound of formula Iis

wherein R¹ is alkyl, alkenyl, alkynyl, haloalkyl, alkylcarbonyl, alkoxy,hydroxymethyl, cyano, azido, alkoxyiminomethyl, alkylcarbonylamino,alkylaminomethyl or dialkylaminomethyl; R² R² is hydrogen, hydroxy,alkoxy, or halogen; R³ and R⁴ are hydrogen, hydroxy, alkoxy, halogen orhydroxyalkyl, provided that at least one of R³ and R⁴ is hydrogen; or R³and R⁴ represent fluorine. and pharmaceutically acceptable saltsthereof; for the preparation of a medicament for the treatment ofdiseases mediated by the Hepatitis C Virus (HCV).
 4. The method of claim3, wherein the compounds of formula I are 4′-C-ethynylcytidinehydrochloride (1:1) 4′-C-ethoxycytidine 4′-C-acetylcytidine
 5. Themethod of claim 3, wherein the compound is 4′-C-azidocytidine.
 6. Themethod of claim 1, wherein the compound is delivered in a dose ofbetween 1 and 100 mg/kg/body weight of the patient/day.
 7. The method ofclaim 5, wherein the compound is delivered in a dose of between 1 and100 mg/kg/body weight of the patient/day.
 8. The method of claim 1,further comprising administering an immune system modulator.
 9. Themethod of claim 8, wherein the immune system modulator is an interferon,interleukin, tumor necrosis factor or colony stimulating factor, anantiviral agent or an anti-inflammatory agent.
 10. The method of claim9, wherein the immune system modulator is an interferon.
 11. The use ofa pharmaceutical composition comprising a compound of claim 1 for thetreatment of diseases mediated by the hepatitis C virus (HCV).